摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R)-azido-(3S)-phenylbutanoic acid | 128677-93-0

中文名称
——
中文别名
——
英文名称
(2R)-azido-(3S)-phenylbutanoic acid
英文别名
(2R,3S)-2-azido-3-phenylbutanoic acid
(2R)-azido-(3S)-phenylbutanoic acid化学式
CAS
128677-93-0
化学式
C10H11N3O2
mdl
——
分子量
205.216
InChiKey
YQSDHKHARGOUQR-IONNQARKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    51.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Asymmetric synthesis of unusual amino acids: An efficient synthesis of optically pure isomers of β-methylphenylalanine.
    作者:Ramalinga Dharanipragada、Katia VanHulle、Anne Bannister、Soaring Bear、Lisa Kennedy、Victor J Hruby
    DOI:10.1016/s0040-4020(01)81570-2
    日期:1992.6
    These acids were attached to the appropriate - or -auxiliary (a 4-phenylmethyl-2-oxazolidinone) to give a 3′-phenylbutanoyl-4-phenylmethyl-2-oxazolidinone. Asymmetric bromination was accomplished via the ciral imide enolate bromination methodology of Evans and co-workers (J. Am. Chem. Soc.1990112, 4011-40). Evidence for asymmetric induction was obtained from the X-ray structure of one of the intermediate
    许多α-氨基酸的非对映体β-氢的取代为肽结构的三维形貌控制提供了一种方法。需要氨基酸的不对称合成来促进这些研究。β-甲基苯丙氨酸,(2S,3S)-,(2R,3R)-,(2S,3R)-和(2R,3S)-β-甲基苯丙氨酸的所有四个单独的异构体均以高光学纯度合成。通过选择起始材料(+)-或(-)-3-苯基丁酸来设定β中心的立体化学。将这些酸与适当的-或-辅助的(4-苯基甲基-2-恶唑烷酮)连接,得到3'-苯基丁酰基-4-苯基甲基-2-恶唑烷酮。不对称溴化是通过Evans和同事的柠檬酰亚胺烯醇盐溴化方法完成的(J.Am. 化学 Soc。1990年112,4011-40)。从中间体溴化物之一的X射线结构获得了不对称诱导的证据。使用四甲基胍叠氮化物通过S N 2置换将溴化物转化为非对映异构叠氮化物。通过催化水解回收手性助剂后,通过在10%Pd / C上催化氢化获得手性氨基酸。所有四种异构体均以95:5至99:1的对映体纯度获得。
  • Asymmetric synthesis of unusual amino acids: Synthesis of optically pure isomers of β-methylphenylalanine
    作者:Ramalinga Dharanipragada、Ernesto Nicolas、Geza Toth、Victor J. Hruby
    DOI:10.1016/s0040-4039(01)93366-0
    日期:1989.1
    All the four individual isomers of β-methylphenylalanine have been synthesized in very high optical purities by utilizing in part the chiral imide enolate bromination methodology of Evans and co-workers.
    β-甲基苯丙氨酸的所有四个单独的异构体都是通过部分地利用Evans和他的同事们的手性酰亚胺烯醇式溴化方法合成的,具有很高的光学纯度。
  • Amino acid derivative
    申请人:Eisai Co., Ltd.
    公开号:US05679671A1
    公开(公告)日:1997-10-21
    The present invention relates to an amino acid derivative having an angiotensin I-converting enzyme inhibition activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibition activity. This amino acid derivative is represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom or an acyl group; R.sup.2 represents a hydrogen atom, a lower alkyl group, a cycloalkyl group, an ary group which may have a substituent, a heteroaryl group which may have a substituent, an arylalkyl group which may have a substituent or a heteroarylalkyl group which may have a substituent; m and n represent each independently an integer of 0, 1 or 2 and J represents a cyclic group having an angiotensin I-converting enzyme inhibition activity.
    本发明涉及一种具有抑制血管紧张素I转化酶活性、抗利尿素激素拮抗作用和心房利钠肽水解酶抑制活性的氨基酸衍生物。该氨基酸衍生物由以下一般式(I)表示:其中R.sup.1代表氢原子或酰基;R.sup.2代表氢原子、较低的烷基、环烷基、可能具有取代基的芳基、可能具有取代基的杂环芳基、可能具有取代基的芳基烷基、可能具有取代基的杂环芳基烷基;m和n分别独立地表示为0、1或2的整数,J代表具有抑制血管紧张素I转化酶活性的环状基团。
  • Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
    申请人:Hoveyda Hamid R.
    公开号:US20110105389A1
    公开(公告)日:2011-05-05
    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
    本发明提供了新型构象定义的大环化合物,已被证明是生长激素分泌素受体(GRLN,生长激素分泌素受体,GHS-R1a及其亚型、异构体和/或变种)的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的拮抗剂或逆向激动剂,以及用于治疗和预防一系列医学疾病,包括但不限于代谢和/或内分泌紊乱、肥胖和与肥胖相关的疾病、食欲或进食紊乱、成瘾紊乱、心血管疾病、胃肠道疾病、遗传疾病、过度增殖性疾病、中枢神经系统疾病和炎症性疾病。
  • AMINO ACID DERIVATIVE
    申请人:Eisai Co., Ltd.
    公开号:EP0671172A1
    公开(公告)日:1995-09-13
    An amino acid derivative having an angiotensin I-converting enzyme inhibitor activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibitor activity, and represented by general formula (I) wherein R¹ represents hydrogen or acyl; R² represents hydrogen, lower alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; m and n represent each independently an integer of 0.1 or 2; and J represents a cyclic group having an angiotensin I-converting enzyme inhibitor activity.
    一种具有血管紧张素Ⅰ转换酶抑制剂活性、血管加压素拮抗剂活性和心房钠尿肽水解酶抑制剂活性的氨基酸衍生物,由通式(I)表示 其中R¹代表氢或酰基;R²代表氢、低级烷基、环烷基、任选取代的芳基、任选取代的杂芳基、任选取代的芳烷基或任选取代的杂芳基烷基;m和n各自独立地代表0.1或2的整数;J代表具有血管紧张素I-转化酶抑制剂活性的环状基团。
查看更多